Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Phase IB 1Nevus 1Neoplasms, Plasma Cell 1Lymphoma 1Lymphangioma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemangioma 1Hemangioendothelioma 1Hamartoma Syndrome, Multiple 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Bone Neoplasms 1Autistic Disorder 1Arteriovenous Malformations 1

Interventions

sulforaphane 1relatlimab 1cemiplimab 1Sirolimus 1Prednisone 1Nivolumab 1Everolimus 1Dermoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Skin Neoplasms × Everolimus × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡